Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20102

Sort by

Sort Order Select

Journal Articles

Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia

Grigorios Tsaknakis, Anna Gallì, Stavros Papadakis, Peggy Kanellou, Chiara Elena, Gabriele Todisco, Elisa Bono, Ettore Rizzo, Elisabetta Molteni, Irene Fragiadaki, Irene Mavroudi, Charalampos Pontikoglou, Anastasios Batas, Stella Maxouri, Emmanouela Linardaki, Nektarios Tavernarakis, Luca Malcovati, Helen A. Papadaki

Blood (2021) 138 (14): 1249–1257.

https://doi.org/10.1182/blood.2021010815

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

Shuo Ma, John F. Seymour, Danielle M. Brander, Thomas J. Kipps, Michael Y. Choi, Mary Ann Anderson, Kathryn Humphrey, Abdullah Al Masud, John Pesko, Ruby Nandam, Ahmed Hamed Salem, Brenda Chyla, Jennifer Arzt, Amanda Jacobson, Su Young Kim, Andrew W. Roberts

Blood (2021) 138 (10): 836–846.

https://doi.org/10.1182/blood.2020009578

Published: 2021

Includes: Supplemental data

Journal Articles

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL

Sameer A. Parikh, Kari G. Rabe, Neil E. Kay, Timothy G. Call, Wei Ding, Jose F. Leis, Saad S. Kenderian, Eli Muchtar, Yucai Wang, Amber B. Koehler, Susan M. Schwager, Connie E. Lesnick, Geffen Kleinstern, Daniel Van Dyke, Curtis A. Hanson, Esteban Braggio, Susan L. Slager, Tait D. Shanafelt

Blood (2021) 138 (2): 149–159.

https://doi.org/10.1182/blood.2020009813

Published: 2021

Includes: Supplemental data

Journal Articles

Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura

Erika Tarasco, Lukas Bütikofer, Kenneth D. Friedman, James N. George, Ingrid Hrachovinova, Paul N. Knöbl, Masanori Matsumoto, Anne Sophie von Krogh, Isabella Aebi-Huber, Zuzana Cermakova, Magdalena Górska-Kosicka, Katarzyna A. Jalowiec, Carlo R. Largiadèr, Zoltán Prohászka, György Sinkovits, Jerzy Windyga, Bernhard Lämmle, Johanna A. Kremer Hovinga

Blood (2021) 137 (25): 3563–3575.

https://doi.org/10.1182/blood.2020009801

Published: 2021

Includes: Supplemental data

Journal Articles

Acalabrutinib in treatment-naive chronic lymphocytic leukemia

John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O’Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Stephen Devereux, Peter Hillmen, John M. Pagel, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Nitin Jain, William G. Wierda

Blood (2021) 137 (24): 3327–3338.

https://doi.org/10.1182/blood.2020009617

Published: 2021

Includes: Supplemental data

Journal Articles

On the road to optimized BTK inhibition in CLL

Lukáš Smolej

Blood (2021) 137 (24): 3313–3314.

https://doi.org/10.1182/blood.2021011462

Published: 2021

Journal Articles

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry

Blood (2021) 137 (20): 2838–2847.

https://doi.org/10.1182/blood.2020010529

Published: 2021

Includes: Supplemental data

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Blood (2021) 137 (17): 2321–2325.

https://doi.org/10.1182/blood.2020009432

Published: 2021

Includes: Supplemental data

Journal Articles

Familial patterns of hematologic precursors

Ola Landgren, Francesco Maura

Blood (2021) 137 (15): 1992–1993.

https://doi.org/10.1182/blood.2020010035

Published: 2021

Journal Articles

Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

Blood (2021) 137 (15): 2046–2056.

https://doi.org/10.1182/blood.2020006322

Published: 2021

Includes: Supplemental data

Journal Articles

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group

Lisa Giulino-Roth, Qinglin Pei, Allen Buxton, Rizvan Bush, Yue Wu, Suzanne L. Wolden, Louis S. Constine, Kara M. Kelly, Cindy L. Schwartz, Debra L. Friedman

Blood (2021) 137 (11): 1449–1456.

https://doi.org/10.1182/blood.2020007225

Published: 2021

Includes: Supplemental data

Journal Articles

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Pamela B. Allen, Hatice Savas, Andrew M. Evens, Ranjana H. Advani, Brett Palmer, Barbara Pro, Reem Karmali, Eric Mou, Jeffrey Bearden, Gary Dillehay, Robert A. Bayer, Robert M. Eisner, Joan S. Chmiel, Kaitlyn O’Shea, Leo I. Gordon, Jane N. Winter

Blood (2021) 137 (10): 1318–1326.

https://doi.org/10.1182/blood.2020007400

Published: 2021

Includes: Supplemental data

Journal Articles

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia

Naranie Shanmuganathan, Ilaria S. Pagani, David M. Ross, Sahee Park, Agnes S. M. Yong, Jodi A. Braley, Haley K. Altamura, Devendra K. Hiwase, David T. Yeung, Dong-Wook Kim, Susan Branford, Timothy P. Hughes

Blood (2021) 137 (9): 1196–1207.

https://doi.org/10.1182/blood.2020005514

Published: 2021

Includes: Supplemental data

Journal Articles

Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma

Paolo Strati, Preetesh Jain, Ralph J. Johnson, Sheryl Forbes, Lei Feng, Felipe Samaniego, Maria A. Rodriguez, Luis E. Fayad, Fredrick Hagemeister, Jason Westin, Michael Wang, Sattva S. Neelapu, Loretta J. Nastoupil, Nathan H. Fowler

Blood (2021) 137 (8): 1124–1129.

https://doi.org/10.1182/blood.2020007994

Published: 2021

Includes: Supplemental data

Journal Articles

Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037.

Blood (2021) 137 (8): 1131.

https://doi.org/10.1182/blood.2021010665

Published: 2021

Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Blood (2021) 137 (8): 1019–1023.

https://doi.org/10.1182/blood.2020008164

Published: 2021

Includes: Supplemental data

Journal Articles

Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults

Blood (2020) 136 (10): 1201–1211.

https://doi.org/10.1182/blood.2020005590

Published: 2020

Includes: Supplemental data

Journal Articles

Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study

Andrea C. Lo, Belinda A. Campbell, Tom Pickles, Christina Aquino-Parsons, Laurie H. Sehn, Joseph M. Connors, Kerry J. Savage

Blood (2020) 136 (8): 1006–1010.

https://doi.org/10.1182/blood.2019004588

Published: 2020

Includes: Supplemental data

Journal Articles

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Blood (2020) 136 (8): 936–945.

https://doi.org/10.1182/blood.2020005288

Published: 2020

Includes: Supplemental data

NARROW

Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL

Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura

Acalabrutinib in treatment-naive chronic lymphocytic leukemia

On the road to optimized BTK inhibition in CLL

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Familial patterns of hematologic precursors

Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia

Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma

Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037.

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults

Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only